CVS Health

Four Reportable Segments

CVS reports Health Care Benefits, Health Services, Pharmacy & Consumer Wellness, and Corporate/Other. Health Care Benefits is primarily Aetna. Health Services includes Caremark, specialty/mail pharmacy, Oak Street, Signify and provider enablement. Pharmacy & Consumer Wellness includes retail pharmacy, vaccinations, infusion and front-store products. [S1]

FY2025 Revenue Architecture

FY2025 segment revenue:

Health Care Benefits           $143.354B
Health Services                $190.425B
Pharmacy & Consumer Wellness   $139.367B
Corporate / Other                $0.484B
Intersegment eliminations      -$71.563B
----------------------------------------
Consolidated                   $402.067B

[S1]

The elimination is crucial. Aetna can buy services from Caremark; Caremark can use CVS Pharmacy or specialty fulfillment. Internal revenue disappears at consolidation.

FY2025 Profit Architecture

CVS's principal segment measure is adjusted operating income.

Health Care Benefits            $2.939B
Health Services                 $7.151B
Pharmacy & Consumer Wellness    $6.040B
Corporate / Other              -$1.687B
---------------------------------------
Consolidated adjusted OI       $14.443B

[S1]

GAAP operating income was materially lower because 2025 contained large impairments, litigation and other items. Both views matter: adjusted results show operating trends; GAAP captures the economic/accounting consequences of prior investments and liabilities.

Latest State — Q2 2026

Q2 2026 consolidated revenue was $106.096B, up 7.3%. Full-year guidance was raised to at least $414B revenue, $7.90–$8.10 adjusted EPS and at least $11.5B operating cash flow. The filed quarterly report provides the corresponding GAAP statements and disclosures. [S3][S4][S5]

                        Revenue      Adjusted OI
HCB                     $37.538B      $2.426B
Health Services         $51.795B      $1.733B
Pharmacy & Consumer     $33.816B      $1.475B
Corporate                $0.147B     -$0.477B
Eliminations           -$17.200B
---------------------------------------------
Consolidated           $106.096B      $5.157B

[S3][S43]

Integrated Model

The integrated model is easiest to see through a Medicare member. Aetna finances and manages the benefit. Caremark may manage prescription coverage. Signify can identify risk in the home. Oak Street can deliver longitudinal primary care. CVS Pharmacy can improve medication access/adherence. Health100 can surface the next action digitally.

The system creates value only if the combined intervention lowers total cost or improves experience/outcomes—not merely if profit shifts among subsidiaries.

Health Care Benefits Economics

Insurance profit is fundamentally underwriting and care-cost management.

premium revenue
- medical claims
- operating expense
= insurance operating profit

The Medical Benefit Ratio (MBR) is health-care costs divided by premium revenue. It was 91.2% in 2025 and 87.4% in Q2 2026. [S1][S42]

Insured vs ASC

In insured plans Aetna bears most medical-cost risk. In administrative-services contracts the employer/plan sponsor bears most of the risk while Aetna earns administration/network fees. The same member-service infrastructure can therefore produce very different revenue, capital and volatility.

Medicare Advantage

Medicare Advantage combines government financing with private plan design, network management, risk adjustment and quality incentives. Aetna integrates supplemental benefits, pharmacy and care-delivery capabilities. For 2027, Signify Healthy Home Visits were included across Aetna MA plans, and more than 69% of Aetna MA members were in plans rated four stars or higher. [S32][S33]

Aetna Margin Recovery

Health Care Benefits went through a severe margin reset as medical costs exceeded prior pricing assumptions. 2025 adjusted operating income improved to $2.939B; in Q2 2026 it reached $2.426B versus $1.308B a year earlier. The Q2 MBR improved by 250 bps year over year. [S1][S42]

The recovery came from pricing, Government-business execution, reserve development and absence of a prior-year premium-deficiency charge—not from simply growing membership.

Caremark PBM

Caremark managed pharmacy benefits for roughly 87 million members and processed about 1.9B 30-day-equivalent prescriptions in 2025. [S1][S44]

A PBM designs formularies and pharmacy networks, adjudicates claims, negotiates manufacturer economics, manages specialty/mail fulfillment and offers clinical programs. Its customer is usually a plan sponsor—not the retail patient.

Why PBM Revenue Is Huge

Health Services revenue contains substantial prescription-drug flows, so the segment can show extremely high revenue with a relatively modest operating-margin percentage. Revenue is not comparable with software revenue. More useful indicators include claims, client retention, specialty mix, purchasing economics, drug mix and adjusted operating income.

TrueCost

TrueCost is the PBM pricing model. It offers drug-level net-cost guarantees and visibility into administrative fees rather than relying only on aggregate market-basket guarantees. [S27][S28]

TrueCost should never be confused with CostVantage. TrueCost governs Caremark-to-client economics; CostVantage governs reimbursement paid to CVS Pharmacy.

Specialty Pharmacy and Cordavis

Specialty medicines are high-cost, clinically complex and often require authorization, patient support and specialized logistics. CVS Specialty operates this layer. Cordavis moves CVS further upstream by working with manufacturers to commercialize biosimilars; CVS cites accelerated Humira-biosimilar adoption as evidence of the integrated Caremark–Specialty–Cordavis strategy. [S30][S31]

Pharmacy & Consumer Wellness

The segment operated roughly 9,000 retail locations, filled 1.8B 30-day-equivalent prescriptions in 2025 and dispensed about 28.5% of U.S. retail pharmacy prescriptions. Pharmacy represented 82.9% of segment revenue. [S1]

CostVantage

CostVantage changes retail-pharmacy reimbursement. Conceptually:

underlying drug cost
+ defined markup
+ dispensing / service fee
= CVS Pharmacy reimbursement

It launched for commercial payors in 2025 and is intended to reduce cross-subsidization across drugs. [S27]

Care Delivery

CVS Health Care Delivery connects Oak Street, Signify and MinuteClinic. Oak Street provides longitudinal primary care for older adults. Signify performs in-home evaluations. MinuteClinic provides convenient ambulatory and virtual care. [S19] These are distinct care models serving different intensity levels.

Oak Street Health

Oak Street operates 230+ centers across 27 states in current CVS materials. Its model uses smaller panels and multidisciplinary care teams for older adults. Value-based contracts allow it to invest in prevention and care coordination if those activities reduce downstream hospital use. [S19][S20]

Signify Health

Signify brings clinicians into the home and captures more than 300 clinical/social data points. CVS says it performed more than 3.5M in-home evaluations in 2025, affecting more than 16M care gaps. [S21][S22] The strategic value is follow-up action, not the visit itself.

MinuteClinic

MinuteClinic operates 800+ clinics and 24/7 virtual care, with more than 190 services. [S23][S24] It is a convenient-care layer, not the same as Oak Street's longitudinal risk model.

Health100 & Haio

Health100 launched in 2026 as a health-technology subsidiary with Google Cloud. It aims to connect prescriptions, records, benefits, spending and care even for consumers who use third-party plans, PBMs or providers. Haio is the AI assistant. [S34][S35][S36]

If successful, Health100 becomes an interface above CVS's fragmented brands. If unsuccessful, it becomes another health app competing for attention.

GLP-1s as an Integration Test

GLP-1s show CVS's integrated reach: Caremark manages coverage, CVS pharmacy can dispense, pharmacists support adherence, MinuteClinic offers weight-management care and Aetna finances benefits. CVS made GLP-1 access a 2026 enterprise focus. [S5][S45]

Regulatory Exposure

CVS touches insurance, PBMs, pharmacy, controlled substances, government programs, providers and health data. In October 2026 CVS agreed to pay $315M to resolve federal opioid-dispensing/False Claims Act allegations. DOJ states the resolved claims were allegations only and there was no determination of liability. [S46]

Why CVS Is Health Care Services

MSCI moved CVS from Drug Retail to 35102015 Health Care Services in April 2018. [S39] The current six-digit GICS Industry canonical is 351020 Health Care Providers & Services. Aetna does not move the entire enterprise into Managed Health Care because CVS's principal integrated services profile is broader.

Related Entities

• Health Care Benefits
• CVS Caremark
• CVS Pharmacy
• CVS Health Care Delivery
• Health100 & Haio
• Health Care Providers & Services

Company System Deep Dive

CVS Health owns businesses on both sides of multiple health-care transactions. Aetna can pay providers and pharmacies. Caremark can design pharmacy benefits. CVS Pharmacy can receive reimbursement. Oak Street can take medical risk. Signify can identify risk in homes.

This creates a powerful information and operating system—but only if internal incentives do not undermine client trust.

Insurance vs PBM vs Pharmacy Margin

These businesses should never be compared with one margin lens. Insurance carries claims risk. PBM revenue contains drug flows. Retail pharmacy has acquisition and labor cost. Primary care may accept risk over total medical cost. The same $1 of revenue does not have the same capital requirement or risk.

Government Exposure

CVS receives significant revenue ultimately tied to federal/state health programs. In 2025, federal-government revenues represented roughly a quarter of consolidated revenue, primarily through CMS-related coverage. [S1] Government policy changes can therefore affect enterprise economics directly.

Reserve Accounting

Health insurers estimate unpaid medical claims before final invoices arrive. Prior-period favorable or unfavorable development can change current earnings. Investors should separate core current-period medical trend from reserve-development effects.

Goodwill / Acquisition Accounting

CVS's major deals created large goodwill/intangible balances. The 2025 Health Services goodwill impairment is evidence that expected acquisition economics can be revised downward. A non-cash impairment does not mean the acquired operations disappear, but it is a signal that prior expected value was not fully supported.

PBM Regulatory Debate

PBMs argue that scale and negotiation lower drug costs; critics focus on rebate incentives, spread pricing, pharmacy reimbursement and vertical integration. CVS's response includes TrueCost, point-of-sale rebate pass-through and biosimilar initiatives. The evidence should present contract mechanics and outcomes rather than adopt either side's rhetoric.

Pharmacy Network Economics

A retail pharmacy can be strategically important yet economically stressed. Pharmacists perform more clinical tasks while reimbursement is negotiated by third parties. CostVantage is an attempt to make the local pharmacy economics more explicit.

Care Delivery Capital Risk

Oak Street centers require leases, clinical teams and patient ramp before mature economics. Signify requires a national clinician network. These are not software products; scaling them requires operating capacity.

Digital Strategy

Health100 is strategically different from earlier CVS apps because it aims to sit above company boundaries and invite third-party connections. The question is whether consumers trust an integrated data/AI layer enough to use it as a persistent health interface.

2026 Watchlist

• Aetna 2027 pricing and medical trend.
• Medicare Star Ratings and bonus economics.
• Caremark client retention / TrueCost adoption.
• Retail-pharmacy reimbursement stability under CostVantage.
• Oak Street mature-center economics.
• Signify follow-up care conversion.
• Health100 active usage and third-party connections.
• Debt / capital allocation after 2023 acquisitions.

Company FAQ

Is CVS primarily an insurer?

No. Insurance is large, but Health Services and Pharmacy & Consumer Wellness are also enormous.

Does CVS force Aetna members to use CVS Pharmacy?

Plan/network designs vary. Integration does not mean every consumer interaction must use a CVS-owned asset.

Why does Health Services revenue exceed Aetna revenue?

PBM revenue includes large prescription-drug flows and intersegment activity; revenue scale is not the same as margin or enterprise value.

Why did CVS buy providers?

To influence medical outcomes and total cost rather than only finance or dispense care.

What is the biggest strategic risk?

Complexity: integration must improve outcomes/cost while preserving trust, competitive choice and regulatory compliance.

The Four Economic Engines in One Company

CVS Health is unusually difficult to analyze because its businesses earn money in fundamentally different ways.

Insurance — take medical-cost risk

Aetna collects premium and, on insured products, pays medical claims. The core underwriting question is whether premium was priced correctly relative to future utilization and unit cost.

PBM — administer and manage drug-benefit economics

Caremark processes claims, manages formularies and networks, negotiates manufacturer economics and provides mail/specialty services. A large amount of drug cost can flow through reported revenue, so PBM revenue margin percentages look structurally different from insurance or software.

Pharmacy — dispense medicines and provide local clinical services

CVS Pharmacy buys or receives drugs through distribution channels and is reimbursed by PBMs, insurers, government programs and patients. The key issue is whether reimbursement adequately covers drug acquisition cost, labor and pharmacy service.

Care delivery — earn from visits, services and/or medical-cost performance

Oak Street, Signify and MinuteClinic create revenue through clinical services and, in selected value-based arrangements, through managing the total cost or outcomes of a population.

These engines can reinforce each other, but their accounting and risk should never be collapsed into one generic “health-care margin.”

How Money Can Move Through the CVS System

Consider one hypothetical Aetna member who uses CVS assets.

employer / CMS pays premium or plan funding
↓
Aetna administers benefit / bears risk
↓
Caremark manages pharmacy benefit
↓
member fills at CVS Pharmacy or another network pharmacy
↓
Signify identifies care gap at home
↓
Oak Street / provider follows up
↓
claims and clinical outcomes feed future care management

Several CVS businesses may record revenue from different legs of that journey.

At consolidation, internal transactions are eliminated.

That is why segment revenue is useful for understanding activity, but consolidated revenue is the only correct company-wide top line.

Why Intersegment Eliminations Are Strategically Important

Intersegment eliminations were $71.563 billion in FY2025. [S1]

That number is not an accounting footnote to ignore.

It shows how much business occurs between CVS-owned operating units.

Examples can include:

• Caremark arrangements involving CVS pharmacies;
• Aetna using Caremark pharmacy-benefit services;
• internal care-delivery relationships.

Large internal volume can create real enterprise efficiencies, but it can also make segment growth appear stronger than consolidated growth.

The analysis should therefore separate two questions:

1. Is a segment growing because it won external customers? 2. Or because another CVS unit bought more services from it?

Both can be useful, but they mean different things competitively.

Insurance Reserve Mechanics

Insurance earnings are partly based on estimates.

Medical claims may be incurred before all claims are finally submitted and paid.

Aetna therefore estimates liabilities for claims incurred but not yet fully reported.

Later periods can show:

• favorable prior-period development when actual claims are lower than estimated;
• unfavorable development when actual claims are higher.

That means a quarterly improvement in Health Care Benefits earnings can come from both current-period operations and updates to prior-period estimates.

Q2 2026 included favorable prior-period development as one contributor to improved HCB results. [S3][S42]

This is why MBR and adjusted operating income should be read together with reserve-development commentary rather than treated as pure current-quarter demand metrics.

Why Medical Trend Can Break an Insurance Year

Aetna prices many products before the full future medical-cost environment is known.

Important cost drivers include:

• hospital utilization;
• outpatient procedures;
• physician prices;
• specialty drugs;
• GLP-1 utilization;
• behavioral health;
• Medicare coding/risk adjustment;
• unit-cost inflation.

If utilization accelerates after pricing is set, premium can be inadequate.

The company then needs to:

• reprice future products;
• change benefits;
• exit unattractive geographies/products;
• improve care management;
• accept lower near-term margins until repricing catches up.

This was central to CVS's 2024–2026 Health Care Benefits story.

The PBM Client Value Proposition

Caremark has to prove value to employers and health plans that can switch PBMs.

A client evaluates more than nominal rebates.

It may care about:

• total net drug spend;
• member out-of-pocket cost;
• formulary disruption;
• specialty management;
• pharmacy access;
• data/reporting;
• implementation quality;
• transparency;
• trend guarantees.

TrueCost is partly a response to the industry's transparency debate by moving more pricing to explicit drug-level economics and visible administration fees. [S29][S32]

The commercial test is not whether the pricing model sounds simpler.

It is whether clients believe total cost is lower and predictable while member experience remains acceptable.

The Pharmacy Reimbursement Problem

A community pharmacy can fill more prescriptions and still experience margin pressure.

For each prescription, the pharmacy economics depend on:

payer / PBM reimbursement
-
drug acquisition cost
-
pharmacist / technician labor
-
store / dispensing overhead
=
pharmacy contribution

Traditional reimbursement can overpay some prescriptions and underpay others.

CVS argues CostVantage reduces this cross-subsidy by tying reimbursement more explicitly to underlying cost plus markup and service fee. [S29][S31]

The key future evidence is whether the model produces:

• stable network economics;
• competitive client cost;
• sustainable patient access.

Specialty Drugs Are the Center of Gravity in Drug Spend

The strategic importance of specialty pharmacy is greater than the number of specialty prescriptions suggests.

Complex biologics and rare-disease therapies can cost tens or hundreds of thousands of dollars per patient per year.

Managing them involves:

• prior authorization;
• site of care;
• adherence;
• cold chain;
• lab monitoring;
• manufacturer programs;
• biosimilar conversion.

Caremark, CVS Specialty and Cordavis form a vertical stack around this spend.

That can create savings through purchasing and coordinated utilization, but it also intensifies scrutiny around pharmacy steering and conflicts of interest.

Why Oak Street Is Economically Different From MinuteClinic

MinuteClinic typically solves convenience problems.

Oak Street solves longitudinal risk-management problems.

MinuteClinic

A visit may address:

• infection;
• vaccination;
• minor injury;
• screening;
• selected chronic-care need.

The economic unit is often a visit or episode.

Oak Street

A primary-care relationship may involve:

• repeated visits;
• transportation/social support;
• medication review;
• specialist coordination;
• hospital follow-up;
• risk-bearing economics.

The economic unit can be the total annual medical cost of a patient population, not one encounter.

This is why Oak Street requires different staffing, capital and performance metrics.

How Signify Can Create Value After the Home Visit

An in-home evaluation is only valuable if information leads to action.

The chain is:

home visit
↓
identify condition / medication issue / social risk
↓
close documentation gap
↓
share actionable information
↓
connect patient to PCP / specialist / benefit
↓
change care outcome

If the chain stops at data collection, the clinical value is limited.

CVS's integration thesis depends on creating reliable follow-up into Aetna, provider and pharmacy workflows.

Health100 as an Enterprise Interface Layer

CVS has accumulated businesses through decades of M&A.

The consumer sees brands that were built separately:

• CVS Pharmacy;
• Aetna;
• Caremark;
• Oak Street;
• Signify;
• MinuteClinic.

Health100's strategic job is not to erase those operating brands.

It is to create a common digital layer above them.

A successful health front door would need to solve four problems:

1. Identity — know who the person is across systems. 2. Data permission — connect records/benefits lawfully and transparently. 3. Navigation — convert information into a useful next action. 4. Execution — actually book, refill, message, pay or connect care.

Haio becomes valuable only when it can move through those steps safely rather than simply answer generic health questions.

Vertical Integration: Where the Value Could Be Real

The strongest integration use cases are those where two CVS assets solve one cost problem better together.

Examples:

Medication adherence

Aetna/Caremark identify nonadherence → CVS Pharmacy engages member → fewer complications.

High-risk Medicare member

Aetna identifies risk → Signify home visit → Oak Street or network PCP follows up → hospital use falls.

Specialty therapy

Caremark manages benefit → CVS Specialty coordinates therapy → medical/pharmacy teams monitor outcomes.

GLP-1 treatment

Benefit design + clinical eligibility + pharmacy fulfillment + ongoing weight-management support.

The integration thesis is strongest when there is a measurable reduction in total cost or improvement in quality.

Vertical Integration: Where Conflicts Can Arise

The same ownership structure can create incentives to favor CVS-owned channels.

Examples of questions clients/regulators may ask:

• Does Caremark prefer CVS-owned pharmacies for economic reasons?
• Does Aetna steer members to CVS providers?
• Are internal transfer prices competitive?
• Do independent pharmacies receive fair reimbursement?
• Does the consumer retain meaningful choice?

These questions do not prove wrongdoing.

They are structural governance questions created by vertical integration.

Debt and Acquisition Returns

CVS used large amounts of capital for Aetna, Oak Street and Signify.

Those acquisitions created:

• debt;
• goodwill;
• intangible assets;
• integration cost;
• return hurdles.

A transaction can be strategically coherent and still destroy shareholder value if the price paid is too high or the acquired earnings fail to materialize.

The most useful return questions are:

• Does acquired cash flow exceed financing cost?
• Are synergies real and durable?
• Is goodwill later impaired?
• Does the asset strengthen other CVS businesses?

The 2025 Health Services goodwill impairment is a reminder that strategic narratives must ultimately reconcile with financial outcomes. [S1]

Government Exposure

CVS is heavily connected to federal and state health programs.

The federal government represented roughly a quarter of 2025 revenue, largely through CMS-related programs. [S1]

Government policy can therefore affect:

• Medicare Advantage premiums;
• Part D;
• Medicaid;
• drug pricing;
• pharmacy reimbursement;
• Star Ratings;
• risk adjustment;
• PBM rules.

This makes policy execution a core operating variable rather than a remote external risk.

Enterprise 2026 Watchlist

Health Care Benefits

Can MBR remain near target after the 2026 recovery?

Medicare Advantage

Do 2027 Star Ratings and pricing support durable margins?

Caremark

Can TrueCost improve transparency without weakening client economics?

Pharmacy

Does CostVantage produce sustainable reimbursement and stable share?

Oak Street

Do mature-center economics justify the acquisition price and expansion capital?

Signify

Do home visits lead to measurable care-gap closure and downstream cost savings?

Health100

Does the platform gain active users outside CVS-owned benefits?

Balance sheet

Does CVS create enough cash to reduce leverage while continuing dividend and technology investment?

Company-Level FAQ

Is CVS an insurer now?

It owns a major insurer, but company economics are broader: PBM, pharmacy and care delivery are all material.

Why is Health Services revenue larger than total company revenue?

It is not larger after consolidation. Segment revenue contains intercompany transactions that are eliminated.

Why can Aetna membership decline while insurance profit improves?

CVS can exit or reprice unprofitable membership. Lower membership can produce better margins if retained business is priced more appropriately.

Why does CVS own doctors?

To influence outcomes and total medical cost more directly, particularly in value-based Medicare populations.

What is the core strategic risk?

That integration adds complexity and regulatory conflicts faster than it creates measurable cost savings and better consumer experience.